Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Lung Cancer. 2010 May 5;71(1):82–88. doi: 10.1016/j.lungcan.2010.04.008

Table 3. PI3K/PTEN/AK17mTOR pathway genotypes and disease progression.

SNP and Genotype Local Progression Distant Progression
Yes No HR* 95% CI P value Yes No HR* 95% CI P value
AKT1:rs3803304 58 97 112 43
 CC 28 47 1.00 57 18 1.00
 CG 22 45 0.80 0.45 to 1.42 0.448 44 23 0.61 0.41 to 0.92 0.017
 GG 8 5 1.59 0.71 to 3.54 0.261 11 2 0.97 0.50 to 1.86 0.921
 CG + GG 0.93 0.55 to 1.57 0.790 0.66 045 to 0.97 0.035
AKT1:rs2494738 65 99 117 47
 AA 52 82 1.00 96 38 1.00
 AG 12 17 0.94 0.49 to 1.79 0.847 20 9
 GG 1 0 1 0
 AG+GG 0.99 0.53 to 1.86 0.985 0.80 0.49 to 1.29 0.357
AKT1:rs2498804 64 99 116 47
 GG 24 38 1.00 49 13 1.00
 GT 30 53 0.80 0.46 to 1.40 0.432 52 31 0.47 0.31 to 0.72 < 0.001
 TT 10 8 1.26 0.60 to 2.68 0.540 15 3 0.76 0.42 to 1.37 0.357
 GT + TT 0.89 0.53 to 1.50 0.661 0.52 0.35 to 0.77 0.001
AKT1:rs1130214 64 99 116 47
 GG 35 49 1.00 63 21 1.00
 GT 24 43 0.74 0.43 to 1.27 0.275 45 22 0.60 0.40 to 0.90 0.013
 TT 5 7 0.91 0.35 to 2.36 0.840 8 4 0.77 0.36 to 1.63 0.492
 GT+TT 0.76 0.45 to 1.28 0.305 0.62 0.42 to 0.91 0.016
AKT2:rs892119 65 97 114 48
 AA 46 66 1.00 80 32 1.00
 AG 18 29 0.93 0.53 to 1.63 0.788 32 15 0.83 0.54 to 1.25 0.370
 GG 1 2 0.97 0.13 to 7.26 0.973 2 1 0.68 0.16 to 2.84 0.595
 AG + GG 0.93 0.53 to 1.61 0.790 0.82 0.54 to 1.23 0.328
AKT2:rs8100018 60 98 110 48
 CC 30 55 1.00 57 28 1.00
 CG 24 35 1.17 0.67 to 2.02 0.588 43 16 1.31 0.86 to 1.93 0.208
 GG 6 8 1.09 0.43 to 2.76 0.856 10 4 1.30 0.66 to 2.56 0.456
 CG + GG 1.15 0.68 to 1.93 0.599 1.30 0.88 to 1.92 0.181
FRAP1:rs11121704 65 98 115 48
 CC 34 54 1.00 64 24 1.00
 CT 26 38 1.14 0.67 to 1.94 0.622 43 21 0.73 0.49 to 1.10 0.130
 TT 5 6 1.34 0.51 to 3.57 0.553 8 3 0.81 0.38 to 1.74 0.593
 CT + TT 1.17 0.71 to 1.94 0.528 0.75 0.51 to 1.09 0.129
FRAP1:rs2295080 63 101 117 47
 GG 26 50 1.00 55 21 1.00
 GT 30 44 1.21 0.71 to 2.06 0.486 51 23 0.77 0.52 to 1.13 0.186
 TT 7 7 1.70 0.72 to 4.03 0.224 11 3 0.91 0.47 to 1.77 0.784
 GT + TT 1.28 0.77 to 2.12 0.343 0.79 0.55 to1.14 0.215
PIK3CA:rs7651265 65 99 116 48
 AA 53 81 1.00 94 40 1.00
 AG 11 18 0.96 0.50 to 1.85 0.901 21 8 0.98 0.60 to 1.58 0.919
 GG 1 0 1 0
 AG + GG 1.04 0.55 to 1.96 0.902 1.02 0.64 to 1.64 0.921
PIK3CA:rs7640662 65 99 116 48
 CC 46 73 1.00 83 36 1.00
 CG 16 25 1.1 0.60 to 2.02 0.753 31 10 1.06 0.69 to 1.64 0.791
 GG 3 1 2.29 0.67 to 7.81 0.186 2 2 0.48 0.11 to 2.01 0.312
 CG + GG 1.20 0.68 to 2.12 0.538 0.99 0.65 to 1.52 0.974
PIK3CA:rs7621329 65 99 117 47
 CC 44 66 1.00 79 31 1.00
 CT 17 31 0.71 0.40 to 1.26 0.238 34 14 0.76 0.51 to 1.15 0.197
 TT 4 2 1.95 0.68 to 5.61 0.213 4 2 0.77 0.27 to 2.21 0.629
 CT + TT 0.82 0.48 to 1.39 0.460 0.76 0.51 to 1.14 0.183
PIK3CA:rs6443624 65 100 117 48
 AA 38 59 1.00 69 28 1.00
 AC 22 38 0.81 0.47 to 1.39 0.439 44 16 0.88 0.59 to 1.30 0.516
 CC 5 3 1.66 0.63 to 4.39 0.307 4 4 0.58 0.20 to 1.65 0.307
 AC + CC 0.91 0.55 to 1.51 0.705 0.84 0.58 to 1.22 0.360
PIK3CA:rs2699887 65 98 115 48
 AA 34 56 1.00 67 23 1.00
 AG 25 34 1.28 0.76 to 2.18 0.353 37 22 0.77 0.51 to 1.17 0.225
 GG 6 8 1.17 0.47 to 2.89 0.733 11 3 0.92 0.47 to 1.80 0.800
 AG + GG 1.26 0.77 to 2.08 0.362 0.80 0.54 to 1.18 0.258
PTEN:rs2299939 61 96 110 47
 AA 45 64 1.00 77 32 1.00
 AC 15 27 0.78 0.42 to 1.43 0.416 31 11 0.94 0.61 to 1.44 0.770
 CC 1 5 1.54 0.20 to 11.82 0.681 2 4 1.16 0.28 to 4.80 0.839
 AC + CC 0.80 0.44 to 1.45 0.466 0.95 0.62 to 1.45 0.806
PTEN:rs12569998 65 100 117 48
 GG 48 73 1.00 83 38 1.00
 GT 15 27 1.10 0.60 to 2.02 0.761 32 10 1.34 0.86 to 2.07 0.195
 TT 2 0 2 0
 GT + TT 1.23 0.69 to 2.19 0.492 1.40 0.91 to 2.14 0.127
PTEN:rs12357281 65 100 117 48
 CC 56 91 1.00 105 42 1.00
 CG 8 9 0.94 0.42 to 2.07 0.876 11 6 0.98 0.51 to 1.88 0.945
 GG 1 0 1 0 1.10 0.14 to 8.41 0.929
 CG + GG 1.08 0.51 to 2.29 0.848 0.99 0.53 to 1.84 0.969
*

adjusted for age, gender, clinical stage, performance status, and smoking status